Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RAH RAH RAH RAH- KEEP BUYING KEEP BUYING. SNDD FOREVER SNDD THE BEST SNDD RAH RAH
Uber- They are in the middle of multiple Toxic deals as we sit here today . Stock is getting hammered because of them.
RED- Our boys and Girls have read all your communications- it seems you might be the brightest mind on this board. Answer the question- Who is this? LAFAYETTE, La., Dec. 13, 2017 (GLOBE NEWSWIRE) -- RedHawk Holdings Corp. (OTCQB:IDNG) (“RedHawk” or the “Company”) announced today that it has received a favorable order from the Circuit Court of the Twelfth Judicial Circuit Court in the State of Florida (Case No. 2017 CA 5554) granting the Company approval of a settlement transaction (the “Transaction”) for RedHawk to issue up to $117,000 of its common stock (“Issued Shares”) in full satisfaction of up to $153,000 of 3rd party trade obligations and broker fees. The Issued Shares are exempt from registration pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended, and will be issued at a 35% discount to market, as defined. DOES ANYONE KNOW WHO THESE CREDITORS ARE THAT WERE ISSUED THIS SETTLEMENT. DOES ANYONE KNOW?
LAFAYETTE, La., Dec. 13, 2017 (GLOBE NEWSWIRE) -- RedHawk Holdings Corp. (OTCQB:IDNG) (“RedHawk” or the “Company”) announced today that it has received a favorable order from the Circuit Court of the Twelfth Judicial Circuit Court in the State of Florida (Case No. 2017 CA 5554) granting the Company approval of a settlement transaction (the “Transaction”) for RedHawk to issue up to $117,000 of its common stock (“Issued Shares”) in full satisfaction of up to $153,000 of 3rd party trade obligations and broker fees. The Issued Shares are exempt from registration pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended, and will be issued at a 35% discount to market, as defined. DOES ANYONE KNOW WHO THESE CREDITORS ARE THAT WERE ISSUED THIS SETTLEMENT. DOES ANYONE KNOW?
Pursuant to a certificate of designation filed with the Secretary of State of the State of Nevada, effective November 12, 2015, 2,750 shares of our authorized Preferred Stock have been designated as Series A 5% Convertible Preferred Stock, originally with a $1,000 stated value (which we refer to as “Series A Preferred Stock”). The holders of the Series A Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, payable quarterly in cash, or at the Company’s option, such dividends shall be accreted to, and increase, the stated value of the issued Series A Preferred Stock (which we refer to as “PIK”). Holders of the Series A Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series A Preferred Stock may be converted. After six months from issuance, each share of Series A Preferred Stock is convertible, at the option of the holder, into the number of shares of common stock equal to the quotient of the stated value, as adjusted for PIK dividends, by $0.015, as adjusted for stock splits and dividends.
Pursuant to a certificate of designation filed with the Secretary of State of the State of Nevada, effective February 16, 2016, 1,250 shares of our authorized Preferred Stock have been designated as Series B 5% Convertible Preferred Stock, originally with a $1,000 stated value (which we refer to as “Series B Preferred Stock”). The holders of the Series B Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, payable quarterly in cash, or at the Company’s option, such dividends shall be accreted to, and increase, the stated value of the issued Series B Preferred Stock (which we refer to as “PIK”). Holders of the Series B Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series B Preferred Stock may be converted. After six months from issuance, each share of Series B Preferred Stock is convertible, at the option of the holder, into the number of shares of common stock equal to the quotient of the stated value, as adjusted for PIK dividends, by $0.01, as adjusted for stock splits and dividends.
During the year ended June 30, 2019 and 2018, we paid-in-kind $156,261 and $148,686, respectively, of related preferred stock dividends.
Keep Buying CODY CO -In March 2016, we authorized the issuance of up to $1 million in principal amount of convertible promissory notes (which we refer to as the “Fixed Rate Convertible Notes”). The Fixed Rate Convertible Notes are secured by certain Company real estate holdings.
The Fixed Rate Convertible Notes issued mature on March 15, 2021, the fifth anniversary of the date of issuance and are convertible into shares of our common stock at a price of $0.015 per share. Interest accrues at a rate of 5% per annum and is payable semi-annually. The Company has the option to issue a notice of its intent to redeem, for cash, an amount equal to the sum of (a) 120% of the then outstanding principal balance, (b) accrued but unpaid interest and (c) all liquidated damages and other amounts due in respect of the Fixed Rate Convertible Notes. The Company may only issue the notice of its intent to redeem the Fixed Rate Convertible Notes if the trading average of the Company’s common stock equals or exceeds 300% of the conversion price during each of the five business days immediately preceding the date of the notice of intent to redeem. The holder of the Fixed Rate Convertible Notes has the right to convert all or any portion of the Fixed Rate Convertible Notes at the conversion price at any time prior to redemption.
During the year ended June 30, 2019, concurrent with the execution of the Exchange Agreement more fully described in Note 9, holders of $515,247 aggregate principal amount of the Company’s 5% convertible promissory notes (“Notes”), including accrued interest, converted their Notes into 103,132,226 shares of Common Stock. At June 30, 2019, there were approximately $135,000 of Fixed Rate Convertible Notes outstanding, of which $76,068 of Notes was converted into 15,213,646 shares of Common Stock subsequent to June 30, 2019. The remaining $50,000 of Fixed Rate Convertible Notes (plus accrued interest) are convertible into our common stock at a conversion rate of $0.015 per share or 3,922,066 shares. During the years ended June 30, 2019 and 2018, we paid-in-kind $29,294 and $29,943, respectively, of interest on these convertible notes.
F-12
During the year ended June 30, 2019, we also issued $334,622 of convertible notes to third parties with variable conversion rates (“Variable Rate Convertible Notes”). The Variable Rate Convertible Notes mature at various dates between September and November 2019. We received, net of financing costs incurred, $289,622 in cash from the issuance of these notes. These Variable Rate Convertible Notes have interest accruing at rates ranging between 10% - 12%, and redemption. These notes issued to third parties have a variable conversion rate based on the price of the Company’s common stock. At June 30. 2019, $256,500 of the convertible notes are currently convertible into our Common Stock beginning in the quarter ending September 30, 2019. During the year ended June 30, 2019, holders of Variable Rate Convertible Notes converted $290,885 of notes, including accrued interest, into 465,397,050 shares of Common Stock. Subsequent to June 30, 2019, we also paid in full three convertible notes in the amount of $154,250 and notes totaling $41,250 were converted into equity.
The Variable Rate Convertible Notes have maturity dates prior to June 30, 2020 and could be classified as a current liability. However, it is the Company’s expectation that we will either re-finance these convertible notes to longer terms or permit a limited amount of conversions. Therefore, we have classified these notes as noncurrent. If we do not re-finance these convertible notes to longer terms, however, the holders of the convertible notes have the option to convert these notes into equity or hold the convertible notes to maturity.
Also, during the year ended June 30, 201, we issued $29,250 of convertible notes to our majority stockholder in exchange for 7,450,000 shares of our common stock. The note matures in December 2020 and is convertible into 1,950,000 shares, or $0.015 per share. (See Note 5.)
In February 2018, we obtained a $100,000 line of credit from a bank. The line of credit matures in February 2021 and is collateralized by a $100,000 certificate of deposit at the bank. As of June 30, 2019, approximately $100,000 was drawn under the line of credit. The interest rate on the line of credit is 7.0% per annum.
On March 12, 2019, we obtained a $180,000 real estate loan from a financial institution. The note matures on April 1, 2020 and is secured by certain real estate property and the personal guarantee of an officer and director of the Company. Interest only is payable monthly and accrues at an interest rate of 12%.
In the quarter ended June 30, 2019, we entered into a series of credit financing arrangements from financing institutions by pledging future accounts receivable. The proceeds from these credit agreements were used to pay the initial amount due under the Schreiber settlement agreement. As of June 30, 2019, we had drawn approximately $150,000 under these agreements. Subsequent to June 30, 2019, we have paid off approximately $50,000 of these loans.
In the year ended June 30, 2019, certain members of the board of directors and stockholders of the Company made $172,000 in interest free advances to the Company. Subsequent to June 30, 2019, $10,000 of these advances were repaid. The remaining advances are convertible into shares of the Company’s common stock at rates ranging from $0.0024 to $0.0050 or 49,250,000 shares. WOW - LOOK AT THIS . Where were the form 4's ? UNBELIEVABLE
Going Concern
We continue to incur operating losses and use cash in our operating activities and are dependent upon asset sales, obtaining third party financing or shareholder loans to pursue any acquisitions and continue our operating activities. For these reasons, there is substantial doubt that we will be able to continue as a going concern without further financing. DILUTION DILUTION DILUTION
LAFAYETTE, La., Dec. 13, 2017 (GLOBE NEWSWIRE) -- RedHawk Holdings Corp. (OTCQB:IDNG) (“RedHawk” or the “Company”) announced today that it has received a favorable order from the Circuit Court of the Twelfth Judicial Circuit Court in the State of Florida (Case No. 2017 CA 5554) granting the Company approval of a settlement transaction (the “Transaction”) for RedHawk to issue up to $117,000 of its common stock (“Issued Shares”) in full satisfaction of up to $153,000 of 3rd party trade obligations and broker fees. The Issued Shares are exempt from registration pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended, and will be issued at a 35% discount to market, as defined. DOES ANYONE KNOW WHO THESE CREDITORS ARE THAT WERE ISSUED THIS SETTLEMENT. DOES ANYONE KNOW
During the fiscal year ended June 30, 2019, certain stockholders of the Company made $110,000 in interest free advances to the Company. Please tell our boys and girls what happened to these Interest Free Loans? Another major question mark?. We hope these have not gone to line Insider pockets. Boys and Girls are digging
(1) On June 20, 2019, the Company entered into a Stock Exchange Agreement (“Exchange Agreement”) with Beechwood. G. Darcy Klug, the Company’s Chairman of the Board, Interim Chief Executive Officer and Chief Financial Officer, is the sole member and manager of Beechwood. Under the Exchange Agreement, the Company purchased from Beechwood 113,700,000 shares of the Company’s common stock in exchange for 1,277 shares of the Company’s Series A Preferred Stock and a Stock Purchase Warrant (“Warrant”) to acquire 113,508,450 shares of the Company’s common stock at an exercise price of $0.005 per share. The Warrant expires June 20, 2029.
THIS TRANSACTION LOOKS SUSPICIOUS - OUR BOYS AND GIRLS ARE DIGGING IN HARD HERE . They have never seen anything like this ever before. Many questions
Problem here is not the plane- It's the PILOT . Pilot has a bad litigious history and has flown this plane into massive turbulence( DILUTION). This pilot has had a horrific record with this stock and we just need to make sure no gasoline is being siphoned off for insider benefit at the expense of shareholders . ( Interest Free Loans, Exchange agreements etc etc etc.) Bring on the next 10k - that will certainly be our flight path.
WE ARE SO EXCITED FOR THE NEW UPDATED 10k !!!!!!!!Recent Sales of Unregistered Securities
During the fiscal year ended June 30, 2019, we sold the following securities in transactions that were not registered under the Securities Act:
? We issued 568,529,275 shares of common stock upon the conversion of approximately $929,844 of convertible notes that were previously sold to accredited investors; and
? We issued 42,000,000 shares to accredited investors for consulting services totaling approximately $65,000.
Exchange Agreement
THIS ONE IS BEAUTIFUL TO READ- WARRANTS ARE BEAUTIFUL
On June 20, 2019, RedHawk Holdings Corp. entered into a Stock Exchange Agreement (“Exchange Agreement”) with Beechwood. G. Darcy Klug, the Company’s Chairman of the Board, Interim Chief Executive Officer and Chief Financial Officer, is the sole member and manager of Beechwood. Under the Exchange Agreement, the Company purchased from Beechwood 113,700,000 shares of the Company’s common stock, $0.001 par value per share (“Common Stock”), in exchange for 1,277 shares of the Company’s 5% Series A Preferred Stock and a Stock Purchase Warrant (“Warrant”) to acquire 113,508,450 shares of Common Stock at an exercise price of $0.005 per share (collectively, the “Transactions”). The Warrant expires June 20, 2029.
22
Concurrent with the execution of the Exchange Agreement, holders of $580,108 aggregate principal amount of the Company’s 5% convertible promissory notes (“Notes”), including accrued interest, were offered and converted their Notes into 116,021,700 shares of Common Stock at a conversion price of $0.005 per share. The extinguishment of the notes and the related accrued interest for the shares of common stock resulted in a gain on extinguishment of approximately $419,000 based on the closing price of the common stock as of the exchange date.
Holders of the Series A Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, payable quarterly in cash, or at the Company’s option, such dividends shall be accreted to, and increase, the stated value of the issued Series A Preferred Stock (“PIK dividends”). Holders of the Series A Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series A Preferred Stock may be converted. After six months from issuance, each share of Series A Preferred Stock is convertible, at the option of the holder, into the number of shares of Common Stock equal to the quotient of the stated value, as adjusted for PIK dividends, by $0.015, as adjusted for stock splits and dividends.
Warrants
In conjunction with the Exchange Agreement, Beechwood was issued 113,508,450 warrants to purchase the Company’s common stock at a price of $0.005 per share. The warrants expire in June 2029 and are assignable.
In conjunction with the 2019 Fixed Rate Convertible Notes, the holders of the 2019 Fixed Rate Convertible Notes were issued 20,800,000 warrants to purchase the Company’s common stock at a price of $0.01 per share. The warrants expire ten years from the date of issuance.
23
On July 19, 2019 (the “Effective Date”), RedHawk Holdings Corp. (the “Company”) and its wholly-owned subsidiary, RedHawk Medical Products & Services, along with other affiliated entities, entered into a Consultant Agreement (“Agreement”) with Drew Pinsky, Inc (“DPI”) f/s/o Dr. Drew Pinsky (“Consultant”), for Consultant to be the exclusive spokesperson for the Company’s Sharps Needle and Destruction Device (“SANDD”) mini™, SANDD Pro™ and any related products and/or accessories (“Products”) for an initial period of two (2) years (“Initial Period”), under the terms and conditions described in the Agreement. At the end of the Initial Period, there shall be an automatic, immediately consecutive two (2) year extension period unless DPI, within 60 days of the expiration of the Initial Period, provides written notice of its intention not to extend the Agreement.
Under the Agreement, the Company will pay DPI a royalty equal to 3% of the “Net Sales”, as defined in the Agreement, of the Products but in no event will the royalty be less than $3.50 per SANDD mini™ unit sold and $13.50 per SANDD Pro™ unit sold.
Pursuant to the Agreement, the Company agreed to issue to the Consultant 68,700,000 shares of the Company’s common stock, which is equal to approximately 5% of the Company’s outstanding common stock on a fully diluted basis as of the Effective Date. Further, the Company has agreed to issue to the Consultant, one year after the Effective Date, an additional 68,700,000 shares of the Company’s common stock, unless DPI has provided the Company with written notice of its intention not to extend the Initial Period. As of the date of this Quarterly Report on Form 10-Q, the Company has not yet issued any of the shares pursuant to the Agreement.
9.
STOCKHOLDERS’ EQUITY
On August 20, 2018, by a vote of the majority of our stockholders, we increased the number of our authorized common shares from 1,000,000,000 to 2,000,000,000.
During the fiscal year ended June 30, 2019, certain members of the board of directors and stockholders of the Company made $242,000 in interest free advances to the Company. The advances are convertible into shares of the Company’s common stock at rates ranging from $0.0024 to $0.0050 or 75,916,667 shares of common stock. During the quarter ended December 31, 2019, the Company received notice from the holders of $142,000 of these related parties of their intent to exercise their right to convert their advances into 55,916,667 shares of common stock. The conversion should be completed subsequent to the year ending June 30, 2020.During the fiscal year ended June 30, 2019, certain members of the board of directors and stockholders of the Company made $242,000 in interest free advances to the Company. The advances are convertible into shares of the Company’s common stock at rates ranging from $0.0024 to $0.0050 or 75,916,667 shares of common stock. During the quarter ended December 31, 2019, the Company received notice from the holders of $142,000 of these related parties of their intent to exercise their right to convert their advances into 55,916,667 shares of common stock. The conversion should be completed subsequent to the year ending June 30, 2020.
As of March 31, 2020, we have approximately $387,111 ($304,471 net of accumulated amortization) in intangible assets related to licenses held by EcoGen. Such intangible assets are being amortized over an estimated useful life of 20 years.
In September 2018, the Company acquired the exclusive license rights to certain medical device technology for $450,000, plus a broker’s fee of $17,500. Under the terms of the license agreement, the Company has paid $25,000 plus the first of a total twenty quarterly payments of $21,250. Any remaining payments become immediately payable upon the receipt of final approval by the FDA of devices related to the technology. Additionally, the Company agreed to pay a consulting fee of $1,000 per month for sixty months. The broker’s fee was paid through the issuance of 14 million shares of the Company’s common stock. The quarterly payments and the consulting fee have been suspended at the present time as the Company and the seller negotiate certain disputes related to representations made by the seller at the time the Company acquired the rights. The ultimate date and resolution of this negotiation cannot be estimated at this time. As a result, the Company has included all of the future payments under the original agreement as noncurrent in the accompanying March 31, 2020 and June 30, 2019 consolidated balance sheets.
In the nine months ended March 31, 2020, we issued 20,000,000 shares of Common Stock under the terms of a 2015 consulting agreement as a result of reaching certain milestones related to the development of our needle destruction devices. Under the terms of this consulting agreement, an additional 40,000,000 shares of Common Stock may be issued if other milestones are met.
There were 113,508,450 outstanding warrants as of March 31, 2020 with an exercise price of $0.005 per share. Such warrants are anti-dilutive to EPS and are excluded from the calculation of EPS.
10
At March 31, 2020, including accrued but unpaid interest, there was one remaining 2016 Fixed Rate Convertible Note outstanding which totaling $61,037 and is convertible into 4,069,118 shares of common stock upon conversion of the remaining 2016 Fixed Rate Convertible Note.
During the nine months ended March 31, 2020, we issued in private offerings exempt from registration debt securities in the form of new 2019 Variable Rate Convertible Notes (See Note 7) in the amount of $1,078,862. The proceeds were used for working capital. The 2019 Variable Rate Convertible Notes are convertible into shares of common stock at a variable conversion rate.
During the nine months ended March 31, 2020, we issued in private offerings exempt from registration debt securities in the form of new 2019 Fixed Rate Convertible Notes (See Note 7) in the amount of $832,000. With the proceeds we paid off certain variable rate convertible notes outstanding in the amount of approximately $458,000, plus accrued interest. The 2019 Fixed Rate Convertible Notes mature on the fifth anniversary of the date of issuance and are convertible into shares of our common stock at a price of $0.015 per share and include 25% warrant coverage at $0.01 per share (which we refer to as the “2019 Warrants”).
At March 31, 2020, including accrued but unpaid dividends, there were potentially 205,846,071 shares of common stock issuable upon the conversion of our outstanding Series A Preferred Stock and, including accrued but unpaid dividends, there were potentially 122,796,364 shares of common stock issuable upon the conversion of our outstanding Series B Preferred Stock. The shares of common stock to be issued upon conversion of the warrants and the shares issuable from the conversion of the notes and the Series A and Series B Preferred stock have been excluded from earnings per share calculations because these shares are anti-dilutive.
As of March 31, 2020, the Company had cash of $99,246, a working capital deficit of $991,397 and an accumulated deficit of $7,052,616. The continuation of the Company as a going concern is still dependent upon the continued financial support from its stockholders, the ability to raise equity or debt financing, cash proceeds from the sale of assets and the attainment of profitable operations from the Company’s businesses in order to discharge its obligations. We cannot predict, with certainty, the outcome of our efforts to generate liquidity and profitability, or whether such actions would generate the expected proceeds to the Company. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
Silver Hawc- We appreciate your comments but whatever they say we don't care unless it is in an 8k where their material comments belong. The CFO might give you insider knowledge but not us. TRansparency is what we expect and the 10k will be the document that should have all their dealings in. Uber- Will this dog hunt? Jelly- Do you really think it will hit .001 again ? Crazy little company with big aspirations and no working capital filled WITH huge TOXIC exposure through their misguided deals . We understand from some of you that the cfo is a little man with a big litigious heart. We don't care - we just want a Shareholders meeting called like all companies have. 1.5 billion shares - here we come . ANOTHER HUGE DOWN DAY WITH BIG BIG VOLUME. DIVEST- Feel good to be down 30% in 1 day ?
LAFAYETTE, La., Dec. 13, 2017 (GLOBE NEWSWIRE) -- RedHawk Holdings Corp. (OTCQB:IDNG) (“RedHawk” or the “Company”) announced today that it has received a favorable order from the Circuit Court of the Twelfth Judicial Circuit Court in the State of Florida (Case No. 2017 CA 5554) granting the Company approval of a settlement transaction (the “Transaction”) for RedHawk to issue up to $117,000 of its common stock (“Issued Shares”) in full satisfaction of up to $153,000 of 3rd party trade obligations and broker fees. The Issued Shares are exempt from registration pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended, and will be issued at a 35% discount to market, as defined. DOES ANYONE KNOW WHO THESE CREDITORS ARE THAT WERE ISSUED THIS SETTLEMENT. DOES ANYONE KNOW
NEW CEO has perfect timing! He comes in and the nosedive begins- I am sure he wishes he did better due diligence. Bad stain for him . Once the 138 mill shares are issued we should be north of 1.5 billions shares unless the CFO illegally goes back to preferred shared to improve his position and cause the company to continue to pay him interest. It would be a highly unethical move- let's hope he knows he is being watched. I am sure Investors who bought their stock knowing the debt was reduced will not sit by to be duped by false press releases- let's hope he knows better and the BOD should be watching- Don't want them exposed as well.
LAFAYETTE, La., Dec. 13, 2017 (GLOBE NEWSWIRE) -- RedHawk Holdings Corp. (OTCQB:IDNG) (“RedHawk” or the “Company”) announced today that it has received a favorable order from the Circuit Court of the Twelfth Judicial Circuit Court in the State of Florida (Case No. 2017 CA 5554) granting the Company approval of a settlement transaction (the “Transaction”) for RedHawk to issue up to $117,000 of its common stock (“Issued Shares”) in full satisfaction of up to $153,000 of 3rd party trade obligations and broker fees. The Issued Shares are exempt from registration pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended, and will be issued at a 35% discount to market, as defined. DOES ANYONE KNOW WHO THESE CREDITORS ARE THAT WERE ISSUED THIS SETTLEMENT. DOES ANYONE KNOW
OUR BOYS AND GIRLS JUST FOUND THIS - CASE 2017 CA 5554.
RedHawk Initiates Plan to Eliminate Debt
Transaction Continues Company Goal to Restructure its Balance Sheet Without Dilution
Email Print Friendly Share
December 13, 2017 15:00 ET | Source: RedHawk Holdings Corp.
LAFAYETTE, La., Dec. 13, 2017 (GLOBE NEWSWIRE) -- RedHawk Holdings Corp. (OTCQB:IDNG) (“RedHawk” or the “Company”) announced today that it has received a favorable order from the Circuit Court of the Twelfth Judicial Circuit Court in the State of Florida (Case No. 2017 CA 5554) granting the Company approval of a settlement transaction (the “Transaction”) for RedHawk to issue up to $117,000 of its common stock (“Issued Shares”) in full satisfaction of up to $153,000 of 3rd party trade obligations and broker fees. The Issued Shares are exempt from registration pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended, and will be issued at a 35% discount to market, as defined.
Simultaneous with announcing the Transaction, RedHawk said it has entered into a common stock purchase and sale agreement (the “Purchase and Sale Agreement”) with Beechwood Properties, LLC (“Beechwood”) who beneficially owns approximately 60% of the Company’s outstanding common stock. Mr. G. Darcy Klug, the Company’s Chairman of the Board and Chief Financial Officer owns and controls Beechwood.
Under the terms of the Purchase and Sale Agreement, RedHawk has agreed to purchase from Beechwood a like number shares (the “Beechwood Shares”) to be issued under the Transaction. The purchase price for the Beechwood Shares is also $117,000 and will be paid with the issuance of a promissory note (the “Note”) to Beechwood. The Note will accrue interest at 5% per annum and will mature three years from date of issuance. After two years from its issuance, the Note and any accrued interest, will become convertible into the Company’s Series A Preferred Stock.
The Company said the Transaction and the Sale and Purchase Agreement were entered into with the objective of continuing to restructure the Company’s balance sheet by eliminating approximately $153,000 of 3rd party debt from the balance sheet, preventing shareholder dilution with the Transaction, and preserving cash to be used for future operations and strategic transactions. Additionally, RedHawk said, upon completion of the Transaction, the Beechwood Shares will be returned into the Company’s treasury with no increase in the number of outstanding shares.
RAH RAH RAH RAH - Shareholders must be so Happy with mgmt and their horrific decisions. Toxic deals, Interest Free loans, Exchange Agreements, limited or no working capital, Massive dilution, Preferred Stock games, No oversight from BOD, lawsuits everywhere( how are they paying these bills) , Billions of shares coming, No shareholder meetings, but yes RAH RAH RAH RAH
Shareholders- Ask yourself if the company is selling then you should be selling. If the Company is buying then you should be buying. Simple . This Company is blasting the stock - get out of the way and save your Family money. DILUTION DILUTION DILUTION. DO not stand there and continue to lose money as they open the flood gates . You will Thank Us like many of you have already . It's all right in front of you in the financials . Disaster =TOxic financings. This mgmt has been duped by Toxic Financiers .
sept 15- www.otcmarkets.com. Sept 30th - 10k. Sept is the month we will all see exactly what this mgmt team and BOD did here . DILUTION DILUTION DILUTION the only question is how much? Shareholders need to see. Our Boys and Girls have calls into Zonis, Woundclot and Centri. Our boys and girls like to channel check- not finding much. 714- Can you help us here and dust the cobwebs off these businesses and enlighten us? Also why hasn't Dr. Drew been issued his 138 mill shares? He earned them contractually didn't he? TRANSPARENCY is what we strive for . Raising capital is a material event for SNDD- Why no 8k's ? Can anyone tell 714 and the rest of the shareholders what an " Interest Free EXchange is" ? What is FREE about an " Interest Free Exchange" ? Please help our boys and girls. MORE DISPUTES : SEE BELOW SEE BELOW SEE bELOW In September 2018, the Company acquired the exclusive license rights to certain medical device technology for $450,000, plus a broker’s fee of $17,500. Under the terms of the license agreement, the Company has paid $25,000 plus the first of a total twenty quarterly payments of $21,250. Any remaining payments become immediately payable upon the receipt of final approval by the FDA of devices related to the technology. Additionally, the Company agreed to pay a consulting fee of $1,000 per month for sixty months. The broker’s fee was paid through the issuance of 14 million shares of the Company’s common stock. The quarterly payments and the consulting fee have been suspended at the present time as the Company and the seller negotiate certain disputes related to representations made by the seller at the time the Company acquired the rights. The ultimate date and resolution of this negotiation cannot be estimated at this time. As a result, the Company has included all of the future payments under the original agreement as noncurrent in the accompanying March 31, 2020 and June 30, 2019 consolidated balance sheets.
It will stop getting posted when the questions are answered . Simple
sept 15- www.otcmarkets.com. Sept 30th - 10k. Sept is the month we will all see exactly what this mgmt team and BOD did here . DILUTION DILUTION DILUTION the only question is how much? Shareholders need to see. Our Boys and Girls have calls into Zonis, Woundclot and Centri. Our boys and girls like to channel check- not finding much. 714- Can you help us here and dust the cobwebs off these businesses and enlighten us? Also why hasn't Dr. Drew been issued his 138 mill shares? He earned them contractually didn't he? TRANSPARENCY is what we strive for . Raising capital is a material event for SNDD- Why no 8k's ? Can anyone tell 714 and the rest of the shareholders what an " Interest Free EXchange is" ? What is FREE about an " Interest Free Exchange" ? Please help our boys and girls. MORE DISPUTES : SEE BELOW SEE BELOW SEE bELOW In September 2018, the Company acquired the exclusive license rights to certain medical device technology for $450,000, plus a broker’s fee of $17,500. Under the terms of the license agreement, the Company has paid $25,000 plus the first of a total twenty quarterly payments of $21,250. Any remaining payments become immediately payable upon the receipt of final approval by the FDA of devices related to the technology. Additionally, the Company agreed to pay a consulting fee of $1,000 per month for sixty months. The broker’s fee was paid through the issuance of 14 million shares of the Company’s common stock. The quarterly payments and the consulting fee have been suspended at the present time as the Company and the seller negotiate certain disputes related to representations made by the seller at the time the Company acquired the rights. The ultimate date and resolution of this negotiation cannot be estimated at this time. As a result, the Company has included all of the future payments under the original agreement as noncurrent in the accompanying March 31, 2020 and June 30, 2019 consolidated balance sheets.
our boys and girls think the Train wreck isn't close to ending. DILUTION DILUTION DILUTION - otcmarkets.com. don't hide it- just put the new number out . We all know what's coming. Uber knows what's coming. Jelly knows what's coming. 10k will be a masterpiece for all to read . Toxic deals come back to hurt you . Welcome to SNDD
The quarterly payments and the consulting fee have been suspended at the present time as the Company and the seller negotiate certain disputes related to representations made by the seller at the time the Company acquired the rights. The ultimate date and resolution of this negotiation cannot be estimated at this time. As a result, the Company has included all of the future payments under the original agreement as noncurrent in the accompanying March 31, 2020 and June 30, 2019 consolidated balance sheets. Jelly- WHAT DOES THIS MEAN????
sept 15- www.otcmarkets.com. Sept 30th - 10k. Sept is the month we will all see exactly what this mgmt team and BOD did here . DILUTION DILUTION DILUTION the only question is how much? Shareholders need to see. Our Boys and Girls have calls into Zonis, Woundclot and Centri. Our boys and girls like to channel check- not finding much. 714- Can you help us here and dust the cobwebs off these businesses and enlighten us? Also why hasn't Dr. Drew been issued his 138 mill shares? He earned them contractually didn't he? TRANSPARENCY is what we strive for . Raising capital is a material event for SNDD- Why no 8k's ? Can anyone tell 714 and the rest of the shareholders what an " Interest Free EXchange is" ? What is FREE about an " Interest Free Exchange" ? Please help our boys and girls. MORE DISPUTES : SEE BELOW SEE BELOW SEE bELOW In September 2018, the Company acquired the exclusive license rights to certain medical device technology for $450,000, plus a broker’s fee of $17,500. Under the terms of the license agreement, the Company has paid $25,000 plus the first of a total twenty quarterly payments of $21,250. Any remaining payments become immediately payable upon the receipt of final approval by the FDA of devices related to the technology. Additionally, the Company agreed to pay a consulting fee of $1,000 per month for sixty months. The broker’s fee was paid through the issuance of 14 million shares of the Company’s common stock. The quarterly payments and the consulting fee have been suspended at the present time as the Company and the seller negotiate certain disputes related to representations made by the seller at the time the Company acquired the rights. The ultimate date and resolution of this negotiation cannot be estimated at this time. As a result, the Company has included all of the future payments under the original agreement as noncurrent in the accompanying March 31, 2020 and June 30, 2019 consolidated balance sheets.
22 mill shares trade on a huge down day ! Toxic boys ripped the shit of the CFO today - took him for along Cajun ride down memory lane .001
Uber - there was more than 400k of Cajun Candy - company posted a CASH bonds as well. They must have raised at least 550k or did they do another friendly cozy " Interest Free Loan". Or maybe they did a loan and sold that loan for stock? Is that even possible? We will just make sure nothing they have done is so deep in the grey . Lots of questions our boys and girls need answered. Uber- Do you know any of these board members? Who is the independent directors? Does the board have Insurance?
You mean if The CFO tries to convert his common back into preferred shares. Does nothing but make your situation WORSE as a shareholder . Cfo accrues interest and takes in into even more stock. Our boys and girls are going to scan him like a Centri machine does. By the way where is the Centri business? Interest free loans next . Divest - Open wide more Cajun Candy coming This dog won't hunt- the question is will it still walk. DILUTION DILUTION DILUTION. Toxic boys like EMI are smiling all the way to the bank on the Shareholders back. 10k- Please
Does anyone know how the lawyers are getting paid? We just can't put our arms around it? Our boys and girls are looking hard and deep for the secret sauce. Does anyone know why Dr. Drew hasn't been issued his 138 mill shares ? Divest- U seem to be a bright guy. Do you know? Do you know what is an " Interest free Loan" to the board? Do you how badly Exchange agreements put shareholders at risk? 10k 10k 10k. We are so excited to have ordered Cajun Candy for that showing. Uber- We have Cajon seasoning as well for the popcorn? The team is ready to scrub the 10K . TOXIC crew is smiling today - they took the CFO for a ride.
Uber- Brilliant. Please trademark Cajun Candy ! Brilliant wait until teh real selling starts. Cajun CAndy Specials = " Interest Free Loans". maybe just a different flavor of Cajun Candy
DON'T be SURPRISED OBI - more to come. listen listen to us. DILUTION DILUTION DILUTION DILUTION. OPEN your mouth so the hose can fit . Company is jamming stock so hard down your throat . Thank us for the warning. It's just starting. last time .001
DIvest - What you don't understand is that the shares are outstanding whether you like it or not. All the preferred shares are convertible into common shares and our boys and girls will calculate the real number once all these converts are in common . It's a huge number . These shares are owned by the CFO and they WILL NEVER GO AWAY . Lots of back and forth and exchange and Interest free loans - we will uncover it all for you and yes you will thank us if you haven't already.
Stock is off 70% - it feels like it will go much lower . The price tells you what you need to know. Open your mouth and let this company continue to hose millions of shares down your throat. How does that feel? Not good . TOXIC Financings have a tendency to not feel good. More coming.